Tabas Talks: Navigating A Fib With Soft Pressures

Atrial fibrillation with soft blood pressure is usually a hemodynamic problem, not a routine rate-control problem. When hypotension overlaps with pulmonary edema or heart failure, the key decision is whether the patient is volume depleted, needs immediate electrical cardioversion, or should be anticoagulated now.

Atrial fibrillation with soft pressures

• Volume status first: Soft-pressure AF is safer to approach when volume depletion is obvious; a modest fluid trial can create room for rate control, especially in dehydrated patients such as alcohol-related presentations.
• Pulmonary edema warning: Plethoric IVC or chest x-ray pulmonary edema argues against routine diltiazem-or-beta-blocker reflexes and pushes management toward electrical cardioversion instead.
• Heart failure physiology: AF with heart failure and hypotension is best treated by restoring sinus rhythm, because electrical cardioversion slows the rate and brings back atrial kick to improve cardiac output.
• Sedation before shock: Ketamine and etomidate are practical pre-cardioversion sedatives in this setting, while chemical cardioversion with procainamide can worsen hypotension.
• Recurrent post-shock AF: If cardioversion fails or AF immediately recurs, amiodarone 150 mg over 10 minutes or IV digoxin are the key rescue options, and we get into when each makes more sense in the episode.

Anticoagulation and cardioversion decisions

• Immediate anticoagulation group: Critically ill patients and those with soft pressures should generally receive anticoagulation early, with LMWH favored upfront in admitted patients to reduce handoff failure.
• CHF embolic risk: Atrial fibrillation plus congestive heart failure carries especially high embolic risk, making anticoagulation the default unless a true contraindication is present.
• CHADS-65 trigger: Two or more CHADS-65 risk factors—hypertension, age over 65, diabetes, CHF, or prior stroke or embolism—support anticoagulation now and continued indefinitely.
• Cardioversion without anticoagulation: A young patient with no CHADS-65 risk factors can be cardioverted without anticoagulation if onset is clearly recent or TEE shows no atrial clot.
• Timing nuance for recent AF: Recent-onset atrial fibrillation is not automatically a shock-first problem because many patients convert spontaneously. We walk through when waiting is smarter in the chapter.

References:

1. January CT, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society [published correction appears in J Am Coll Cardiol. 2014 Dec 2;64(21):2305-7]. J Am Coll Cardiol. 2014;64(21):e1-e76. PMID: 24685669
2. Prasai P, et al. Electric Cardioversion vs. Pharmacological with or without Electric Cardioversion for Stable New-Onset Atrial Fibrillation: A Systematic Review and Meta-Analysis. J Clin Med. 2023;12(3):1165. Published 2023 Feb 1. PMID: 36769812
3. Andrade JG, et al. The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation. Can J Cardiol. 2020;36(12):1847-1948. PMID: 33191198
4. Danias PG, et al. Likelihood of spontaneous conversion of atrial fibrillation to sinus rhythm. J Am Coll Cardiol. 1998;31(3):588-592. PMID: 9502640
5. Ergene U, et al. Must antidysrhythmic agents be given to all patients with new-onset atrial fibrillation?. Am J Emerg Med. 1999;17(7):659-662. PMID: 10597083
6. Hindricks G, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC [published correction appears in Eur Heart J. 2021 Feb 1;42(5):507] [published correction appears in Eur Heart J. 2021 Feb 1;42(5):546-547] [published correction appears in Eur Heart J. 2021 Oct 21;42(40):4194]. Eur Heart J. 2021;42(5):373-498. PMID: 32860505
7. January CT, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons [published correction appears in Circulation. 2019 Aug 6;140(6):e285]. Circulation. 2019;140(2):e125-e151. PMID: 30686041
8. Pluymaekers NAHA, et al. Early or Delayed Cardioversion in Recent-Onset Atrial Fibrillation. N Engl J Med. 2019;380(16):1499-1508. Stiell et al. Outcomes for Emergency Department Patients With Recent-Onset Atrial Fibrillation and Flutter Treated in Canadian Hospitals. Ann Emerg Med. 2017;69(5):562-571.e2. PMID: 30883054
9. Stiell IG, et al. 2021 CAEP Acute Atrial Fibrillation/Flutter Best Practices Checklist. CJEM. 2021;23(5):604-610. PMID: 34383280
10. Atzema CL, et al. Prescribing of oral anticoagulants in the emergency department and subsequent long-term use by older adults with atrial fibrillation. CMAJ. 2019;191(49):E1345-E1354.  PMID: 31818927